GSK, Sanofi join Finland genome study

Jan 25, 2019

Sanofi and GlaxoSmithKline have joined an academic-industrial collaboration that aims to contribute to genetic research by ultimately identifying new therapeutic targets and diagnostics for treating numerous diseases.

The FinnGen study, launched in fall 2017, aims to produce comprehensive genome variant data of 500,000 biobank participants, representing one of the largest studies of this type.

Numerous pharma companies, including Biogen, AbbVie, Celgene, Genentech, Pfizer, Merck and AstraZeneca are already on board with the study.

"FinnGen offers an exciting collaborative opportunity to study genetic impacts on human conditions over time in a world class research environment," said Matt Nelson, Head of Human Genetics at GSK.

Read the press release